Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | TNF | P01375 | 11/20 | 0.60 |
| ▸ | PDE4A | P27815 | 4/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693845 | 0.86 | TNF (0.79) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6689047 | 0.81 | TNF (0.64) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6693327 | 0.75 | TNF (0.79) | KMT2ATNFPDE4APDE4BPDE4C | |
| SCHEMBL6691607 | 0.75 | TNF (0.70) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6693790 | 0.74 | TNF (0.65) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6688763 | 0.74 | TNF (1.00) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6693277 | 0.74 | TNF (0.77) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL28722625 | 0.74 | TNF (0.72) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL6688750 | 0.73 | PDE4A (0.68) | KMT2AATMTNFPDE4APDE4B | |
| SCHEMBL8380372 | 0.73 | KMT2A (0.60) | KMT2AATML3MBTL1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-0706521-B1 | IMIDES AS TNF ALPHA INHIBITORS | CELGENE CORP (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |